Revision of the criteria for Alzheimer's disease: A symposium (original) (raw)

Abstract

The current criteria for classification of Alzheimer's disease (AD) have deficiencies that limit drug development, research, and practice. The current standard for the clinical diagnosis of AD, the National Institute of Neurological and Communicative Disorders and Stroke (now known as the National Institute of Neurological Disorders and Stroke), and the Alzheimer's Disease and Related Disorders Association (now known as the Alzheimer's Association) criteria, are nearly 25 years old and have not been revised to incorporate advances in the epidemiology and genetics of AD, studies of clinicopathologic correlations and recent studies of potential diagnostic biomarkers. In a very real sense our ability to diagnose AD with a very high level of certainty has outpaced our current diagnostic criteria. The Alzheimer's Association Research Roundtable convened a meeting in April 2009 to discuss new data and technologies that could, with further development, enable improvements in the clinical diagnosis of AD, especially in its earliest and mildest stages. This meeting reviewed the current standards for detecting and defining the clinical presentation of AD and discussed areas that could contribute to earlier and more accurate definitive clinical diagnosis. These included clinical, neuropsychological, and other performance-based assessments, genetic contributions, and biochemical and neuroimaging biomarkers that could reflect AD pathology and lead to better ascertainment of AD, mild cognitive impairment, and presymptomatic AD.

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (84)

  1. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neu- rology 1984;34:939-44.
  2. Johnson DK, Storandt M, Morris JC, Galvin JE. Longitudinal study of the transition from healthy aging to Alzheimer disease. Arch Neurol 2009;66:1254-9.
  3. DuBois B, Feldman HH, Jacova C, DeKosky ST, Barberger-Gateau P, Cummings J, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007; 6:734-46.
  4. Farias ST, Mungas D, Reed BR, Harvey D, DeCarli C. Progression of mild cognitive impairment to dementia in clinic-vs community-based cohorts. Arch Neurol 2009;66:1151-7.
  5. Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pa- thologies account for most dementia in community-dwelling older per- sons. Neurology 2007;69:2197-204.
  6. Jack C, Knopman D, Jagust W, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's patho- logical cascade. Lancet 2010;9:119-28.
  7. De Leon MJ. Aspects of Alzheimer's disease: an atlas of Alzheimer's disease. Carnforth, England: Parthenon Publishing; 1999.
  8. Dickson DW. Neuropathological diagnosis of Alzheimer's disease: a perspective from longitudinal clinicopathological studies. Neurobiol Aging 1997;18(4 Suppl):S21-6.
  9. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41:479-86.
  10. Markesbey WR, Wang HZ, Kowall NW, Kosik KS, McKee AC. Mor- phometric image analysis of neuropil threads in Alzheimer's disease. Neurobiol Aging 1993;14:303-7.
  11. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathologica 1991;82:239-59.
  12. Morris JC. The challenge of characterizing normal brain aging in re- lation to Alzheimer's disease. Neurobiol Aging 1997;18:388-9.
  13. Khachaturian ZS. Diagnosis of Alzheimer's disease. Arch Neurol 1985;42:1097-105.
  14. Consensus recommendations for the postmortem diagnosis of Alz- heimer's disease. The National Institute on Aging, and Reagan Insti- tute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer's disease. Neurobiol Aging 1997;18(4 Suppl):S1-2.
  15. Mukaetova-Ladinska EB, Xuereb JH, Bargia-Sierra F, Hurt J, Gertz HJ, Hills R, et al. Lewy body variant of Alzheimer inverted ex- clamation Mark's disease: selective neocortical loss of t-SNARE pro- teins and loss of MAP2 and alpha-synuclein in medial temporal lobe. Sci World J 2009;9:1463-75.
  16. Burack MA, Hartlein J, Flores HP, Taylor-Reinwald L, Perlmutter JS, Cairns NJ. In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia. Neurology 2010;74:77-84.
  17. Lee VM, Giasson BL, Trojanowski JQ. More than just two peas in a pod: common amyloidogenic properties of tau and alpha-synuclein in neurodegenerative diseases. Trends Neurosci 2004;27:129-34.
  18. Nakashima-Yasuda H, Uryu K, Robinson J, Xie SX, Hurtig H, Duda JE, et al. Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathologica 2007;114:221-9.
  19. Higashi S, Iseki E, Yamamoto R, Minegishi M, Hino H, Fujisawa K, et al. Concurrence of TRDP-43, tau and alpha-synuclein pathology in brains of Alzheimer's disease and dementia with Lewy body. Brain Res 2007;1184:284-94.
  20. Hamilton RL. Lewy bodies in Alzheimer's disease: a neuropathologi- cal review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol 2000;10:378-84.
  21. Schneider JA, Bennett DA. Where vascular meets neurodegenerative disease. Stroke 2010;41(10 Suppl):S144-6.
  22. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association; 2000.
  23. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed, revised. Washington, DC: American Psychiatric Association; 1987.
  24. Pitner JK, Bachman DL. A synopsis of the practice parameters of de- mentia from the American Academy of Neurology on the diagnosis of dementia. Consult Pharmacol 2004;19:52-63.
  25. Petersen RC, Roberts RO, Knopman DS, Boeve BF, Geda YE, Ivnik RJ, et al. Mild cognitive impairment: ten years later. Arch Neurol 2009;66:1447-55.
  26. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, et al. Vitamin E and donepezil for the treatment of mild cog- nitive impairment. N Engl J Med 2005;352:2379-88.
  27. Winblad B, Gauthier S, Scinto L, Feldman H, Wilcock GK, Truyen L, et al. Safety and efficacy of galantamine in subjects with mild cogni- tive impairment. Neurology 2008;70:2024-35.
  28. Feldman HH, Ferris S, Winblad B, Sfikas N, Mancione L, He Y, et al. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Lancet Neurol 2007;6:501-12.
  29. Thal LJ, Ferris SH, Kirby L, Block GA, Lines CR, Yuen E, et al. A ran- domized, double-blind, study of rofecoxib in patients with mild cogni- tive impairment. Neuropsychopharmacology 2005;30:1204-15.
  30. Folstein MF, Folstein SE, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
  31. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clin- ical scale for the staging of dementia. Br J Psychiatry 1982; 140:566-72.
  32. Reisberg B, Ferris SH, de Leon MJ, Crook T. Global Deterioration Scale (GDS). Psychopharmacol Bull 1988;24:661-3.
  33. Landau SM, Harvey D, Madison CM, Reiman EM, Foster NL, Aisen PS, et al. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology 2010;75:230-8.
  34. Vemuri P, Wiste HJ, Weigand SD, Shaw LM, Trojanowski JQ, Weiner MW, et al. MRI and CSF biomarkers in normal, MCI and AD sub- jects: predicting future clinical change. Neurology 2009;73:294-301.
  35. Foster NL. Barriers to treatment: the unique challenges for physicians providing dementia care. J Geriatr Psychiatry Neurol 2001;14:188-98.
  36. Petersen RC, Negash S. Mild cognitive impairment: an overview. CNS Spectrosc 2008;13:45-53.
  37. Lyketsos C. Neuropsychiatric symptoms (behavioral and psychologi- cal symptoms of dementia) and the development of dementia treat- ments. Int Psychogeriatr 2007;19:409-20.
  38. Steinberg M, Lyketsos CG. Neuropsychiatric measures for cognitive dis- orders. In: Rush AJ, First MB, Blacker D, eds. Handbook of Psychiatric Measures. Washington, DC: American Psychiatric Association; 2008.
  39. Taragano FE, Allegri RF, Krupitzki H, Sarasola DR, Serrano CM. Mild behavioral impairment and risk of dementia: a prospective cohort study of 358 patients. J Clin Psychiatry 2009;70:584-92.
  40. Brouers N, Sleegers K, Van Broeckhoven C. Molecular genetics of Alzheimer's disease: an update. Ann Med 2008;40:562-83.
  41. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 al- lele and the risk of Alzheimer's disease in late onset families. Science 1993;261:921-3.
  42. Reitz C, Mayeux R. Use of genetic variation as biomarkers for Alz- heimer's disease. Ann N Y Acad Sci 2009;1180:75-96.
  43. Roses AD, Lutz MW, Amrine-Madsen H, Saunders AM, Crenshaw DG, Sundseth SS, et al. A TOMM40 variable-length poly- morphism predicts the age of late-onset Alzheimer's disease. Pharma- cogenomics J 2010;10:375-84.
  44. Hoe HS, Rebeck GW. Functional interactions of APP with the apoE receptor family. J Neurochem 2008;106:2263-71.
  45. Liang WS, Chen K, Lee W, Sidhar K, Corneveaux JJ, Allen AN, et al. Association between GAB2 haplotype and higher glucose metabolism in Alzheimer's disease-affected brain regions in cognitively normal APOE4 carriers. Neuroimage 2011;54:1896-902.
  46. Reitz C, Mayeux R. Use of genetic variation biomarkers for mild cognitive impairment and progression of mild cognitive impairment to dementia. J Alzheimers Dis 2010;19:29-51.
  47. Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neu- ropathol 1995;26:231-45.
  48. Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A, Winblad B, et al. Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early-and late-onset Alzheimer disease and sta- bility during the course of disease. Arch Neurol 1999;56:673-80.
  49. Hampel H, Buerger K, Zinkowski R, Teipel SJ, Goernitz A, Andreasen N, et al. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease; a comparative cerebro- spinal fluid study. Arch Gen Psychiatry 2004;61:95-102.
  50. Vanmechelen E, Vanderstichele H, Davidsson P, Van Kerschaver E, Van Der Perre B, Sjogren M, et al. Quantification of tau phosphory- lated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 2000;285:49-52.
  51. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010; 6:131-44.
  52. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, et al. Association between CSF biomarkers and incipient Alzheimer's dis- ease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006;5:228-34.
  53. Mattsson N, Blennow K, Zetterberg H. CSF biomarkers: pinpointing Alzheimer pathogenesis. Ann N Y Acad Sci 2009;1180:28-35.
  54. Olsson A, Vanderstichele H, Andreasen N, De Meyer G, Wallin A, Holmberg B, et al. Simultaneous measurement of beta-amyloid(1- 42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem 2005;51:336-45.
  55. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD Initiative. Standards for Reporting of Diagnostic Accuracy. Clin Chem 2003;49:1-6.
  56. Fagan AM, Head D, Shah AR, Marcus D, Mintun M, Morris JC, et al. Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol 2009;65:176-83.
  57. Wahlund LO, Blennow K. Cerebrospinal fluid biomarkers for disease stage and intensity in cognitively impaired patients. Neurosci Lett 2003;339:99-102.
  58. Jack CR Jr, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, et al. Serial PIB and MRI in normal, mild cognitive im- pairment and Alzheimer's disease: implications for sequence of path- ological events in Alzheimer's disease. Brain 2009;132:1355-65.
  59. Haense C, Buerger K, Kalbe E, Drzezga A, Teipel SJ, Markiewicz P, et al. CSF total and phosphorylated tau protein, regional glucose me- tabolism, and dementia severity in Alzheimer's disease. Eur J Neurol 2008;15:1155-62.
  60. Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, et al. PET imaging of amyloid deposition in patients with mild cogni- tive impairment. Neurobiol Aging 2008;29:1456-65.
  61. Scheltens P, Fox N, Barkhof F, De Carli C. Structural magnetic reso- nance imaging in the practical assessment of dementia: beyond exclu- sion. Lancet Neurol 2002;1:13-21.
  62. Duara R, Loewenstein DA, Potter E, Appel J, Greig MT, Urs R, et al. Medial temporal love atrophy on MRI scans and the diagnosis of Alz- heimer disease. Neurology 2008;71:1986-92.
  63. Ridha BH, Barnes J, van de Pol LA, Schott JM, Boyes RG, Siddique MM, et al. Application of automated medial temporal lobe atrophy scale to Alzheimer disease. Arch Neurol 2007;64:849-54.
  64. DeCarli C, Frisoni G, Clark CM, Harvey D, Grundman M, Petersen RC, et al. Qualitative estimates of medial temporal lobe atro- phy as a predictor of progression from mild cognitive impairment to dementia. Arch Neurol 2007;64:108-15.
  65. den Heijer T, Geerlings MI, Hoebeek FE, Hofman A, Koudstall PJ, Breteler MM. Use of hippocampal and amygdalar volumes on mag- netic resonance imaging to predict dementia in cognitively intact el- derly people. Arch Gen Psychiatry 2006;63:57-62.
  66. Tapiola T, Pennanen C, Tapiola M, Tervo S, Kivipelto M, Hanninen T, et al. MRI of hippocampus and entorhinal cortex in mild cognitive im- pairment: a follow-up study. Neurobiol Aging 2008;29:31-8.
  67. Sluimer JD, Bouwman FH, Vrenken H, Blankenstein A, Barkhof F, van der Flier WM, et al. Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study. Neurobiol Aging 2010;31:758-64.
  68. Bouwman FH, Schoonenboom SN, van der Flier WM, van Elk EJ, Kok A, Barkhof F, et al. CSF biomarkers and medial temporal love at- rophy predict dementia in mild cognitive impairment. Neurobiol Ag- ing 2007;28:1070-4.
  69. de Leon MJ, Convit A, Wolf OT, Tarshish CY, De Santi S. Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]flouro-2-de- oxy-D-glucose/poitron-emission tomography (FDG/PET). Proc Natl Acad Sci U S A 2001;98:10966-71.
  70. Mosconi L, De Santi S, Li J, Tsui WH, Li Y, Boppana M, et al. Hippo- campal hypometabolism predicts cognitive decline from normal ag- ing. Neurobiol Aging 2008;29:676-920.
  71. Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothia- zoles as amyloid imaging agents. J Med Chem 2003;46:2740-54.
  72. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004;55:306-19.
  73. Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008;131:1630-45.
  74. Choi SR, Golding G, Zhuang Z, Zhang W, Lim N, Hefti F, et al. Pre- clinical properties of 18F-AV-45: a PET agent for ABeta plaques in the brain. J Nucl Med 2009;50:1887-94.
  75. Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, O'Keefe G, et al. Imaging of amyloid beta in Alzheimer's disease with 18F- BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol 2008;7:129-35.
  76. Tolboom N, van der Flier WM, Yagub M, Koene T, Boellaard R, Windhorst AD, et al. Differential association of [11C]PIB and [18F] FDDNP binding with cognitive impairment. Neurology 2009;73:2079-85.
  77. Jagust W. Amyloid 1 activation 5 Alzheimer's? Neuron 2009; 63:141-3.
  78. Mintun MA, Larossa GN, Sheline Dence CS, Lee SY, Mach RH, et al. [11c]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006;67:446-52.
  79. Edison P, Archer HA, Hinz R, Hammers A, Pavese N, Tai YF, et al. Amyloid, hypometabolism, and cognition in Alzheimer dis- ease: an [11C]PIB and [18F]FDG PET study. Neurology 2007; 68:501-8.
  80. Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, et al. Im- aging beta-amyloid burden in aging and dementia. Neurology 2007; 68:1718-25.
  81. Bennet DA, Schneider JA, Arvanitakis Z, Kelly JF, Aggarwal NT, Shah RC, et al. Neuropathology of older person without cognitive impairment from two community-based studies. Neurology 2006; 66:1837-44.
  82. Price JL, McKeel DW Jr, Buckles VD, Roe CM, Xiong C, Grundman M, et al. Neuropathology of nondemented aging: presump- tive evidence for preclinical Alzheimer disease. Neurobiol Aging 2009;30:1026-36.
  83. Hampel H, Frank R, Broch K, Teipel S, Katz R, Hardy J, et al. Bio- markers for Alzheimer's disease; academic, industry and regulatory perspectives. Nat Rev Drug Dev 2010;9:560-74.
  84. Hort J, O'Brien JT, Gainotti G, Pirttila T, Popescu BO, Rektorova I, et al. EFNS guidelines for the diagnosis and management of Alz- heimer's Disease. Eur J Neurol 2010;17:1236-48.